{
  "drug_name": "Ofloxacin",
  "tradename": "Floxin, Oculfox",
  "drug_shortage": [
    {
      "preparation": "0.3% ophthalmic solution",
      "start_date": null,
      "notes": ""
    }
  ],
  "usage_and_dosing": {
    "general": [
      "Ofloxacin, FDA approved in 1990, is a fluoroquinolone with broad activity against respiratory and enteric pathogens.",
      "Ofloxacin is a racemic mixture of R-ofloxacin and L-ofloxacin (levofloxacin).",
      "For most clinical indications, levofloxacin is used rather than ofloxacin.",
      "CDC no longer recommends fluoroquinolones (including ofloxacin) for gonococcal infections due to high levels of resistance (MMWR 2007;56:332).",
      "See Fluoroquinolones, Overview for additional class-wide information."
    ],
    "adult_dose": {
      "usual_dose": "200-400 mg po q12h",
      "dairy": "Avoid dairy products ±2 hours of oral administration.",
      "metal_cations": "Concomitant metal cations: see Major Drug Interactions below."
    },
    "pediatric_dose": {
      "dose_age_gt_28_days": "Safety and efficacy not established",
      "max_day": "-"
    }
  },
  "renal_adjustment": {
    "half_life_normal": "7",
    "half_life_esrd": "28-37",
    "dose_renal_function_normal": "200-400 mg po q12h",
    "crcl_or_egfr": "CrCl >50: No dosage adjustment. CrCl 10-50: 200-400 mg q24h. CrCl <10: 200 mg q24h",
    "hemodialysis": "200 mg q24h (give dialysis day dose AD)",
    "capd": "200 mg q24h",
    "crrt": "200-400 mg q24h",
    "sled": "No data"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_a": "No dosage adjustment",
    "moderate_impairment_child_pugh_b": "No dosage adjustment",
    "severe_impairment_child_pugh_c": "No dosage adjustment"
  },
  "adverse_effects": [
    "Detailed discussion of adverse effects: see Fluoroquinolones, Overview."
  ],
  "pregnancy_risk": {
    "fda_risk_category": "Avoid in pregnancy due to possible renal, cardiac, and CNS toxicity in the fetus. Consider use if no alternatives exist, and if benefit outweighs risk.",
    "lactation": "Avoid breastfeeding for 4-6 hrs after a dose, monitor infant for GI toxicity",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category"
  },
  "antimicrobial_spectrum": {
    "preferred": [
        "Chlamydia trachomatis",
        "Legionella sp."
    ],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "24-hr AUC/MIC",
    "preparations": "Tab (200, 300, 400 mg), 0.3% oph soln, 0.3% otic soln",
    "food_recommendation": "Tab ± food",
    "oral_absorption_percent": "98",
    "tmax_hr": "1-2",
    "peak_serum_conc_ug_ml": "4.6-6.2 (400 mg po q12h, SS)",
    "peak_urine_conc_ug_ml": "No data",
    "protein_binding_percent": "32",
    "volume_of_distribution_vd_l_kg": "1-2.5 L/kg",
    "avg_serum_half_life_hr": "7",
    "elimination": "Renal",
    "bile_penetration_percent": "No data",
    "csf_blood_percent": "No data",
    "therapeutic_levels_in_csf": "No data",
    "auc_ug_hr_ml": "82.4 (400 mg po q12h, 0-24h)"
  },
  "major_drug_interactions": [
      {"drug": "Antacids (Al, Ca, Mg)", "effect": "↓ ofloxacin", "management": "Give 2 hou"},
      {"drug": "Antiarrhythmics (Class IA/III)", "effect": "↑ QT interval", "management": "Avoid co-adr"},
      {"drug": "Calcium supplements", "effect": "↓ ofloxacin", "management": "Give 2 hou"},
      {"drug": "Didanosine", "effect": "↓ ofloxacin", "management": "Give 2 hou"},
      {"drug": "Insulin", "effect": "↑↓ blood glucose", "management": "Mon"},
      {"drug": "Iron supplements", "effect": "↓ ofloxacin", "management": "Give 2 hou"},
      {"drug": "NSAIDS", "effect": "↑ risk of CNS stimulation/seizures", "management": "Monitor ("},
      {"drug": "Oral hypoglycemics", "effect": "↑↓ blood glucose", "management": "Mon"},
      {"drug": "Sucralfate", "effect": "↓ ofloxacin", "management": "Give 2 hou"},
      {"drug": "Theophylline", "effect": "↑ theophylline", "management": "Monitor ("},
      {"drug": "Warfarin", "effect": "↑ INR", "management": "Monitor INR, a"},
      {"drug": "Zinc", "effect": "↓ ofloxacin", "management": "Give 2 hou"}
  ]
}
